NR1H4 and metabolic dysfunction-associated steatotic liver disease: However, since other non-steroidal FXR ligands have proven as effective as OCA in the treatment of NAFLD/NASH without the burden of the above mentioned side effects [5], this receptor should be considered a validated target in treating NASH.